Cyclosporine Eye Drops for Dry Eye Disease
Cyclosporine ophthalmic solution 0.05% should be dosed twice daily (approximately 12 hours apart) for moderate dry eye disease, with the option to reduce to once daily after one full year of therapy in responsive patients. 1
Dosing Recommendations
Standard Dosing
- Initial therapy: One drop in each eye twice daily, approximately 12 hours apart 2
- Long-term maintenance: After 1 full year of twice-daily therapy, the dose can be decreased to once daily in a portion of patients without loss of beneficial effects 1
- Administration: Invert the single-use vial before using; use immediately after opening and discard the remainder 2
Clinical Context for Use
- Cyclosporine is indicated for moderate dry eye disease as an anti-inflammatory therapy, used in addition to aqueous enhancement therapies (artificial tears) 1
- The American Academy of Ophthalmology guidelines position cyclosporine after artificial tears have proven insufficient for symptom control 1
- Success rates range from 67-74% across mild, moderate, and severe dry eye patients 1
Contraindications and Precautions
Absolute Contraindications
- Active ocular infections: The drug label specifies "for ophthalmic use only" but does not list specific contraindications in the provided evidence 2
Important Precautions
- Contact lens wear: Patients should remove contact lenses prior to administration and wait 15 minutes before reinsertion; patients with decreased tear production typically should not wear contact lenses 2
- Pregnancy Category C: No teratogenicity observed in animal studies at doses 300,000 times the human dose, but use only if benefits outweigh risks 2
- Avoid contamination: Do not allow the vial tip to touch the eye or any surface 2
Follow-Up Recommendations
Timeline for Assessment
- Initial response: Evaluate at 6 months for objective improvements (Schirmer test increases of 10mm were noted at this timepoint in 15% of treated patients vs 5% of vehicle) 1
- Intermediate monitoring: Assess at 4,8, and 12 weeks for symptomatic improvement and tolerability 3
- Long-term follow-up: Continue monitoring through 12 months to assess for disease-modifying effects and potential dose reduction 1
Specific Parameters to Monitor
Objective signs:
- Corneal fluorescein staining (expect improvement) 4, 5
- Schirmer tear test (expect 10mm increase in responders) 1
- Tear break-up time 3
- Conjunctival goblet cell density (may increase, though clinical significance unclear) 1
Subjective symptoms:
- Ocular burning (occurs in 17% of patients, typically mild) 1
- Blurred vision, sandy/gritty feeling, dryness, itching 4
- Use of concomitant artificial tears (should decrease) 4
Safety monitoring:
- Intraocular pressure (if corticosteroids are used concurrently) 1
- Visual acuity 3
- Signs of ocular infection 2
Important Clinical Caveats
Evidence Quality Considerations
- A 2019 Cochrane review of 30 RCTs (4,009 participants) concluded that evidence is inconsistent regarding cyclosporine's effects on ocular discomfort and tear film parameters 1
- Despite this, cyclosporine may function as a disease-modifying agent, with prolonged improvement lasting a median of 20 months after discontinuation following 23 months of treatment 1
Common Pitfalls
- Premature discontinuation: Benefits may not be apparent until 6 months of therapy; counsel patients about delayed onset of action 1
- Inadequate baseline therapy: Ensure contributing factors (blepharitis, meibomitis, eyelid malposition) are addressed concurrently 1
- Preservative toxicity: When artificial tears are used more than 4 times daily, switch to preservative-free formulations 1
- Ocular burning: This occurs in 17% of patients but is typically well-tolerated and should not prompt discontinuation unless severe 1